Diabetes patients should have more voice in treatment: experts

October 2, 2012
Diabetes patients should have more voice in treatment: experts
New guidelines say individual, doctor and evidence must all contribute to decisions.

(HealthDay)—New guidelines meant to provide type 2 diabetes patients with truly individualized care have been issued by the American Diabetes Association and the European Association for the Study of Diabetes.

The new position statement recommends more patient involvement in the treatment and management of their condition and gives guidance on the rational approach to the choice of therapy. Choices—including precise goals for —should combine the best available scientific evidence with the doctor's and patient's own preferences.

"Given the uncertainties in terms of type and sequence of therapies, this approach is particularly appropriate in type 2 diabetes," Andrew Boulton, a professor at the University of Manchester, in England, and EASD president, said in a news release from the organization.

Among the other main points in the new guidelines:

  • Diet, exercise and education remain the foundation of any type 2 diabetes treatment program.
  • Unless there are good reasons for not using it, metformin (brand names include Fortamet, Glucophage, Glumetza and Riomet) is the best first-line drug.
  • After metformin, there is limited data to guide treatment. Combination therapy with an additional one or two oral or injectable drugs is reasonable, aiming to minimize side effects where possible.
  • Eventually, many patients will require alone or in combination with other drugs to maintain .
  • Comprehensive cardiovascular risk reduction must be a major focus of therapy.
The guidelines were scheduled for release Tuesday at the annual meeting of the EASD, in Berlin, and appear in the journal Diabetologia.

In the guidelines, patient-centered care is defined as "an approach to providing care that is respective and responsive to individual patient preferences, needs and values, ensuring that the patients' own values guide all clinical decisions."

Ultimately, patients make the final decision about their and, to some degree, the drug treatments they receive. Their diabetes care and management has to fit in with their lives.

Explore further: Patient-centered approach key for T2DM management

More information: The American Diabetes Association has more about diabetes treatment and care.

Related Stories

Patient-centered approach key for T2DM management

April 23, 2012
(HealthDay) -- Treatment of type 2 diabetes should be personalized in a patient-centered approach, with diet, exercise, and education forming the basis of any treatment program, supplemented by medications as necessary, according ...

Diabetes groups issue new guidelines on blood sugar

April 19, 2012
(HealthDay) -- Type 2 diabetes is a complex metabolic disorder, and treating the disease often requires a personalized, multi-pronged approach, say new expert guidelines on treating high blood sugar levels, issued Thursday.

ACP recommends metformin to treat type 2 diabetes based on CE analysis of oral medications

February 6, 2012
The American College of Physicians (ACP) recommends that clinicians add metformin as the initial drug treatment for most patients with type 2 diabetes when lifestyle modifications such as diet, exercise, and weight loss have ...

Patients with Type 2 diabetes may not benefit from oral medication as well as insulin

April 20, 2012
Patients suffering from type 2 diabetes may not benefit from taking both an oral glucose lowering drug (metformin) and insulin instead of insulin alone, a study published on bmj.com claims.

Study shows treating diabetes early, intensively is best strategy

June 28, 2012
Intensive early treatment of type 2 diabetes slows down progression of the disease by preserving the body's insulin-producing capacity, a UT Southwestern study has shown.

Recommended for you

Pancreatic islets study may spur diabetes treatment advances

September 22, 2017
Investigators in the Vanderbilt Diabetes Research and Training Center (VDRTC) and collaborators at Stanford University have discovered new insights into the molecular mechanisms of cell proliferation in juvenile human pancreatic ...

Finding a natural defense against clogged arteries

September 20, 2017
In type 2 diabetes, chronic inflammation drives cardiovascular disease, the leading cause of death among people with the condition. Researchers at Joslin Diabetes Center now have identified an unexpected natural protective ...

Study identifies blood vessel as a therapeutic target for diabetes

September 14, 2017
Blood vessels have an often overlooked role of regulating the transfer of nutrients from the blood to organs in the body. In a new Yale-led study, researchers have identified a role of a secreted protein, apelin, in regulating ...

Drug for type 2 diabetes provides significant benefits to type 1 diabetic patients

September 14, 2017
A majority of patients with Type 1 diabetes who were treated with dapagliflozin, a Type 2 diabetes medicine, had a significant decline in their blood sugar levels, according to a new study published in The Lancet Diabetes ...

Could swine flu be linked to type 1 diabetes?

September 14, 2017
(HealthDay)—Young people who've been infected with the H1N1 swine flu virus may be at increased risk for type 1 diabetes, a new study suggests.

Epigenetic 'fingerprint' identifies diabetes risk

September 14, 2017
Deakin researchers have identified an epigenetic marker that predicts risk of type 2 diabetes in women with gestational diabetes.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.